Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Dec 28, 2021
Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotech company founded by Flagship Pioneering, Founder of Moderna. Using their platform to create compositions of endogenous metabolic modulators, EMMs, Axcella has generated two liver programs including 1125 for treating NASH. Preclinical and clinical data led them to test 1125 for long COVID fatigue in conjunction with Dr. Betty Raman Senior Clinical Research Fellow in the Radcliffe Department of Medicine at the University of Oxford.
Bill explains, "So 1125 is a composition of amino acids and their derivatives, which is put together to address specific biologies. And we have tested it all the way into phase 2b in NASH patients. And what we've seen is it has an effect on important energy aspects, so bioenergetics, along with inflammatory redox, and immune and muscle functions."
"And what happens, in this case, is that basically, the virus comes in, hijacks the mitochondria to help it reproduce or redirect its efforts towards producing more virus. And when it does that, it damages the cell itself and its ability to create energy."
"Dr. Raman likes to talk about the fact that there's a battery, think of it as a rechargeable battery but unfortunately, in this case, the battery is damaged and it can't hold its charge. And so what 1125 is looking to do is to repair the battery's processes through areas like fatty acid oxidation, ATP generation, immune enhancement, as well as inflammatory reduction."
#Axcella #AxcellaLongCovid #AxcellaTherapeutics #OxfordLongCOVID #LongCOVID #COVID19 #COVID #ChronicFatigueLongCOVID #LongHaulers #ClinicalTrials
